PinTherapeutics
Protein degrader with scientific revolution
- Headquarters
- Seongnam
- Employees
- 11–50
- Business Model
- B2B
- Website
- pintherapeutics.com
About
Pin Therapeutics is a South Korean biotech company specializing in Targeted Protein Degradation (TPD), with operations in Seongnam, South Korea and the San Francisco Bay Area. The company has developed two proprietary platforms — PinE3, for discovering novel E3 ligases, and PinGLUE, for identifying novel Molecular Glue Degraders — to overcome the limitations of current TPD technology and build a clinical pipeline for unmet medical needs. Pin Therapeutics raised approximately $15.4 million USD in a Series C round in December 2024, and its lead compound PIN-5018, a CK1α-targeting molecular glue degrader, has entered Phase 1 clinical trials.
Summary
PinTherapeutics is a Biotech company based in Seongnam, South Korea.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/pintherapeutics"><img src="https://indexed.vc/api/badge/company/pintherapeutics" alt="PinTherapeutics on Indexed.vc" width="260" height="76" /></a>